America Handing MRNA Lead: Investors Reassess Biotech
A political shift in the United States is denting confidence in mRNA medicine, with funding drying up and manufacturi...
When faced with surprise expenses, pause, assess impact, and execute a prepped plan: reallocate, delay nonessential spending, and access the buffer.
10,028 articlesA political shift in the United States is denting confidence in mRNA medicine, with funding drying up and manufacturi...
A luxury tax on second homes could reshape New York City's budget and housing market. This article weighs the potenti...
A year of unprecedented cyber thefts saw North Korean-linked groups drain more than $2 billion from financial network...
Tokyo unveils a sweeping move in crypto policy: a flat 20% tax on gains and a gateway for ETFs, paired with legal rec...
Authorities say fake social media campaigns lured thousands into buying the Solana-based CatFi memecoin before the cu...
Markets that did not ride the pandemic rush are delivering resilience as higher rates persist. New data show how the ...
Three Dow components lag this year, sharing three pressure points that investors still see as catalysts. Wall Street ...
On June 11, 2026, Suze Orman advised a caller with $600,000 to manage the portfolio themselves rather than pay a 1.5%...
The University of Wisconsin System fired its president in a unanimous vote after a brief closed-door meeting, leaving...
A wave of selling from retail investors has pulled Wendy's stock lower. This guide explains why that crowd dynamic co...
Stryker and Intuitive Surgical reported divergent Q1 2026 results, underscoring two distinct medtech playbooks. Stryk...
Investors are debating whether SpaceX could tilt investors toward the Nasdaq-100 if the private company ever joins th...